OCC Stock Overview
Orthocell Limited, a regenerative medicine company, develops and commercializes cell therapies and biological medical devices for the repair of various bone and soft tissue injuries in Australia.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Orthocell Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.38 |
| 52 Week High | AU$0.46 |
| 52 Week Low | AU$0.32 |
| Beta | 0.096 |
| 1 Month Change | -3.80% |
| 3 Month Change | -1.30% |
| 1 Year Change | 0% |
| 3 Year Change | -30.28% |
| 5 Year Change | 216.67% |
| Change since IPO | 2.70% |
Recent News & Updates
Recent updates
Shareholder Returns
| OCC | AU Biotechs | AU Market | |
|---|---|---|---|
| 7D | -1.3% | 1.9% | -0.06% |
| 1Y | 0% | -8.1% | 4.3% |
Return vs Industry: OCC exceeded the Australian Biotechs industry which returned -8.1% over the past year.
Return vs Market: OCC underperformed the Australian Market which returned 4.3% over the past year.
Price Volatility
| OCC volatility | |
|---|---|
| OCC Average Weekly Movement | 7.0% |
| Biotechs Industry Average Movement | 11.8% |
| Market Average Movement | 9.0% |
| 10% most volatile stocks in AU Market | 17.7% |
| 10% least volatile stocks in AU Market | 3.5% |
Stable Share Price: OCC has not had significant price volatility in the past 3 months.
Volatility Over Time: OCC's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | n/a | Paul Anderson | orthocell.com |
Orthocell Limited, a regenerative medicine company, develops and commercializes cell therapies and biological medical devices for the repair of various bone and soft tissue injuries in Australia. The company offers CelGro, a naturally derived collagen medical device for use in multiple indications to augment the surgical repair of bone, peripheral nerves, tendons, and cartilage; and Ortho-ATI, a cell therapy for treatment of chronic tendon injuries. It also provides Ortho-ACI, an autologous chondrocyte implantation to treat articular cartilage defects in the knee and ankle; Striate+, a resorbable collagen membrane used for guided bone and tissue regeneration in dental procedure; and Remplir, a collagen scaffold used in peripheral nerve repair.
Orthocell Limited Fundamentals Summary
| OCC fundamental statistics | |
|---|---|
| Market cap | AU$79.54m |
| Earnings (TTM) | -AU$7.42m |
| Revenue (TTM) | AU$4.80m |
16.6x
P/S Ratio-10.7x
P/E RatioIs OCC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| OCC income statement (TTM) | |
|---|---|
| Revenue | AU$4.80m |
| Cost of Revenue | AU$1.39m |
| Gross Profit | AU$3.42m |
| Other Expenses | AU$10.84m |
| Earnings | -AU$7.42m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.035 |
| Gross Margin | 71.12% |
| Net Profit Margin | -154.56% |
| Debt/Equity Ratio | 0% |
How did OCC perform over the long term?
See historical performance and comparison